sk&f 104976 has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentzen, C; Berkhout, TA; Jackson, B; Niesor, E; Patel, DD; Simon, HM; Suckling, KE | 1 |
| Adams, JL; Berkhout, TA; Bossard, MJ; Mayer, RJ | 1 |
2 other study(ies) available for sk&f 104976 and Liver Neoplasms
| Article | Year |
|---|---|
The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Acetates; Anticholesteremic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Diphosphonates; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Kinetics; Lanosterol; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Receptors, LDL; RNA, Messenger; Transcription, Genetic; Tritium; Tumor Cells, Cultured | 1996 |
Effects of a novel lanosterol 14 alpha-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in Hep G2 cells.
Topics: Carcinoma, Hepatocellular; Cell-Free System; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Humans; Hydroxymethylglutaryl CoA Reductases; Lanosterol; Liver Neoplasms; Lovastatin; Mevalonic Acid; Oxidoreductases; Receptors, LDL; Sterol 14-Demethylase; Sterols; Tumor Cells, Cultured | 1991 |